Keyphrases
Neoadjuvant
100%
Anastrozole
80%
Graft-versus-host Disease (GvHD)
75%
Tumor
74%
Breast Cancer
64%
Ki-67
53%
Interferon Receptor
50%
CD30
50%
Chemotherapy
50%
Palbociclib
50%
Lymphoma
47%
Estrogen
46%
Graft-versus-leukemia Effect
45%
CD30 Expression
39%
T Cells
38%
Immunohistochemistry
35%
DNA Damage Response
33%
Cyclin-dependent Kinase 4/6 Inhibitors
33%
HER2-negative Breast Cancer
30%
Multiple Myeloma
30%
Cyclin-dependent Kinase 6 (CDK6)
27%
Early Breast Cancer
27%
Acute Myeloid Leukemia
27%
Tumor Cells
25%
Plasma Cell Neoplasm
25%
Early Outcome
25%
Cytological Samples
25%
BerEP4
25%
Panel Consensus
25%
MOC31
25%
Clonal Identity
25%
Receptor Signaling
25%
Immunohistochemical Tests
25%
S100A9
25%
MK-2206
25%
AKT Inhibitor
25%
PIK3CA mutation
25%
ER-positive
25%
Expert Panel
25%
Cohort Design
25%
Baseline Characteristics
25%
Epidemiology
25%
Physiological Health
25%
Specific Antibodies
25%
Interferon Signaling
25%
ErbB2
25%
Negative Breast Cancer
25%
Phase II Trial
25%
Stimulator of Interferon Genes (STING)
25%
Postmenopausal Patients
25%
Medicine and Dentistry
Breast Cancer
100%
Anastrozole
78%
Neoplasm
54%
Clinical Stage
54%
Immunohistochemistry
50%
Diagnosis
50%
Cyclin-Dependent Kinase 4
50%
Palbociclib
50%
Disease
33%
Multiple Myeloma
31%
Drive
27%
Estrogen Receptor
26%
Tumor Cell
25%
Cohort Analysis
25%
Acute B-Cell Lymphoblastic Leukemia
25%
Fulvestrant
25%
Epithelial Cell Adhesion Molecule
25%
Cytotechnology
25%
Patient Care
25%
Plasmacytoma
25%
Randomized Clinical Trial
25%
Pancreas Adenocarcinoma
25%
Cohort Effect
25%
Antibodies
25%
Cholangiocarcinoma
25%
Gamma Interferon Receptor
25%
Thymidine Kinase 1
25%
Hirschsprung's Disease
25%
Baricitinib
25%
Phase II Trials
25%
Graft Versus Host Reaction
25%
Interleukin 6 Receptor
25%
Pharmacodynamics
25%
Spermiogenesis
25%
Fetoprotein
25%
Human T-Lymphotropic Virus 1
25%
Virus Oncogene
25%
HBZ
25%
Transgenic Mouse
25%
Bone Disease
25%
Biological Marker
23%
Pathologist
20%
Non-Hodgkin Lymphoma
20%
Effusion
18%
Carcinoma
18%
Graft Versus Leukemia Effect
17%
Biopsy
17%
Parasympathetic Nervous System
16%
Programmed Cell Death
16%
Allogeneic Hematopoietic Stem Cell Transplantation
14%